Geographical and temporal distribution of SARS-CoV-2 clades in the WHO European Region, January to June 2020

Project Description

Analyzed the distribution of SARS-CoV-2 genetic clades over time and across countries in the WHO European Region.
Applied three major genomic nomenclature systems to all publicly available sequence data up to 10 July 2020.
Emphasized the importance of real-time sequencing and data sharing during a pandemic.
Provided a comparison of existing genomic classification systems to support consistent tracking.
Laid the groundwork for future genomic surveillance efforts across Europe.

Enabled real-time whole genome sequencing (WGS) during the early stages of the COVID-19 pandemic – the first global health crisis where this technology was widely applied.
Contributed to the collection of over 63,000 complete genome sequences on GISAID by July 2020, with 39,000 from 35 countries in the WHO European Region.
Demonstrated the feasibility of rapid genome data sharing, with 8% of sequences published within 2 weeks of sample collection.
Supported the use and comparison of multiple clade and lineage nomenclature systems (Nextstrain, GISAID, and cov-lineages.org), helping to streamline communication and track outbreaks effectively.
Analyzed the evolution and distribution of viral clades over time and across regions, highlighting shifts in dominant variants such as clades 20A/G, 20B/GR, and 20C/GH.
Applied robust bioinformatics tools including MAFFT, IQ-Tree, and Pangolin, ensuring accurate phylogenetic analysis and data curation.
Addressed critical challenges in data standardization, naming conventions, and data privacy compliance (e.g. GDPR), contributing to international efforts in genomic epidemiology.

Applied standardized virus nomenclatures to the European SARS-CoV-2 dataset, enabling consistent tracking of clades and lineages across countries and over time.
Mapped geographical and temporal trends of major SARS-CoV-2 variants during the first half of 2020 to inform regional public health strategies.
Identified key genomic surveillance objectives at the European level, including tracking variant introductions, transmission dynamics, and mutation impacts.
Assessed the potential influence of genetic changes on diagnostic performance, including both molecular and serological tests.
Contributed to the foundation for evaluating the future effects of mutations on antiviral drug efficacy and potential vaccine escape risks.
Demonstrated the importance of rapid and representative genome sequencing for real-time outbreak analysis, such as tracing events in Beijing and mink farms in the Netherlands.
Showcased the benefits of early data sharing through platforms like GISAID, supporting quick response measures and continuous viral monitoring.
Highlighted the need for flexible surveillance guidance tailored to varying capacities among European countries to ensure equitable and effective genomic monitoring.

Explore the full research here